Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03694392 · ClinicalTrials.gov registry record
Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years
A clinical trial, sponsored by Kaiser Permanente.
- Completed
- Registry status
- 2,776,278
- Enrollment target
NCT03694392: Completed study, sponsored by Kaiser Permanente.
NCT03694392 is a clinical trial that has completed, run by Kaiser Permanente. The registered enrollment target is 2,776,278 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03694392 has completed, sponsored by Kaiser Permanente.
- COMPLETED
- Registry status
- 2,776,278 participants
- Enrollment target
Study Summary
The overall objective of this study is to describe the effectiveness of Flublok Quadrivalent vaccine compared to standard dose inactivated influenza vaccine (SD-IIV) in adults 18 through 64 years of age. During this study, Flublok Quadrivalent or SD-IIV will be administered according to the guidelines in the Prescribing Information materials and only to persons for whom it is indicated. The 2018-2019, 2019-2020, and 2020-2021 formulations of recombinant influenza vaccine (Flublok Quadrivalent vaccine) and SD-IIV will be evaluated for outcomes including all polymerase chain reaction (PCR)-confirmed influenza, PCR-confirmed hospitalized influenza, hospitalized community-acquired pneumonia and cardio-respiratory events.
Primary Outcome
Patients who receive either Flublok or SD-IIV will be retroactively assessed for whether they had a PCR-confirmed positive influenza test (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30).
Interventions
- BIOLOGICAL Flublok Quadrivalent
- BIOLOGICAL Standard Dose Inactivated Influenza Vaccine (SD-IIV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,776,278 participants |
| Start Date | 2018-09-16 |
| Est. Completion | 2022-12-31 |
What the finished NCT03694392 record still lists
NCT03694392 is an observational study that tracks outcomes without assigning an intervention. Its 2,776,278 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Flublok Quadrivalent is the first listed.
NCT03694392 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03694392 about?
NCT03694392 is a clinical study titled "Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years". The overall objective of this study is to describe the effectiveness of Flublok Quadrivalent vaccine compared to standard dose inactivated influenza vaccine (SD-IIV) in adults 18 through 64 years of age. During this study, Flublok Quadrivalent or SD-IIV will be administered according to the guidelin...
What is the current status of trial NCT03694392?
This trial is currently completed. The enrollment target is 2,776,278 participants. The study started on 2018-09-16. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT03694392?
The interventions under investigation include: Flublok Quadrivalent (BIOLOGICAL), Standard Dose Inactivated Influenza Vaccine (SD-IIV) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03694392?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06803498 · 3,000,000 participants
Delivery Room Intervention and Evaluation Network
- NCT03813862 · 2,000,000 participants
Observational Pharmaco-Epidemiology Research & Analysis
- NCT06057181 · 2,000,000 participants
Helix Research Network
- NCT02693223 · 3,892,063 participants
Get With the Guidelines-Stroke Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI